Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Historical liver biopsy consistent with NASH with stage 2-3 fibrosis according to NASH Clinical Research Network (CRN) classification OR clinical diagnosis of nonalcoholic fatty liver disease and screening FibroTest, magnetic resonance imaging - proton density fat fraction (MRI-PDFF), and FibroScan~* Screening laboratory parameters, as determined by central laboratory:~  * Alanine aminotransferase (ALT) ≤ 5 x upper limit of the normal range (ULN)~ * Estimated glomerular filtration rate (eGFR) ≥ 30 milliliter/minute (mL/min), as calculated by the Modification of Diet in Renal Disease (MDRD) study equation~ * HbA1c ≤ 9.5%~ * International normalized ratio (INR) ≤ 1.2, unless due to therapeutic anti-coagulation therapy~ * Platelet count ≥ 100,000/μL~ * Total bilirubin \< 1.3 x ULN unless alternate etiology such as Gilbert's syndrome present~ * Calcitonin ≤ 100 ng/L~* Body Mass Index (BMI) \> 23 kg/m\^2 and body weight of \> 60 kg~Key Exclusion Criteria:~* Any historical liver biopsy consistent with cirrhosis~* Any history of decompensated liver disease, including ascites, hepatic encephalopathy, or variceal bleeding~* Other causes of liver disease, including but not limited to: alcoholic liver disease, hepatitis B, hepatitis C, autoimmune disorders (eg, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), autoimmune hepatitis), drug-induced hepatotoxicity, Wilson disease, clinically significant iron overload, or alpha-1-antitrypsin deficiency requiring treatment~* History of liver transplantation~* History of hepatocellular carcinoma~* History of pancreatitis (acute or chronic)~* Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma~* Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) in the period from 90 days prior to the date of the Screening Visit~* Individuals on antidiabetic medications must be on a stable dose for at least 90 days prior to the date of the Screening Visit and in the period between the date of the Screening Visit and Enrollment (Day -14)~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) for 24 weeks
- Semaglutide + Firsocostat 20 mg (Type: EXPERIMENTAL): Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + firsocostat 20 mg for 24 weeks
- Semaglutide + Cilofexor 30 mg (Type: EXPERIMENTAL): Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + cilofexor 30 mg for 24 weeks
- Semaglutide + Cilofexor 100 mg (Type: EXPERIMENTAL): Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + cilofexor 100 mg for 24 weeks
- Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg (Type: EXPERIMENTAL): Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + firsocostat 20 mg + cilofexor 30 mg for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).